The expression and clinical significance of clusterin and ki67 in cervical cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16554-e16554
Author(s):  
E. Shrestha
Keyword(s):  
Cervical Cancer ◽  
Cell Carcinoma ◽  
Clinical Significance ◽  
Small Cell Carcinoma ◽  
Squamous Epithelium ◽  
Small Cell ◽  
Cancer Center ◽  
Ki67 Expression ◽  
Significant Difference ◽  
Expression Rate

e16554 Background: To explore the expression pattern and clinical significance of the CLU and proliferation indices ki67 in cervical cancer. Methods: 59 cases treated at Cancer Center Sun Yat-sen University during 1989–2006 were enrolled in the study group. The relationship was analyzed for the expressions of CLU and Ki67 with clinical factors. Results: In this study positivity of CLU in cervical SCC, 10% (3/31) cases weak positive, adenocarcinoma 21% (4/19) weak positive in small cell carcinoma 11% (1/9) moderate positive. Control groups, CLU weak positive expression, 21% (3/14) CIN 2–3 and 14% (2/13) normal squamous epithelium.CLU expression found 100% (31/31) normal endocervical glands.The Ki67 in SCC 13% (4/31) cases weak positive and 5% (1/19) adenocarcinoma. All cases small cell carcinoma revealed negative. No significant difference of the CLU expression rate between normal cervical epithelium, CIN II-III and SCC (p = 0.561). No significant difference of CLU expression rate between normal endocervical gland and adenocarcinoma (p = 0.119) as well. In Ki67, there was no significant difference of Ki67 rates between CIN 2–3 and normal squamous epithelium (p = 0.585). No significant difference of Ki67 expression rates between adenocarcinoma and normal squamous epithelium (p = 0.341). The expression of CLU and Ki67 had no correlation with FIGO stage, SCC antigen level, grade of differentiation, deep stromal invasion, and lymph node metastasis. Finally, the expression of CLU and Ki67 was not related to the 5-years DFS rates, and CLU expression was not correlated with Ki67 expression (rs = 0.500, p = 0.391). Conclusions: CLU and Ki67 was in lower rates in cervical cancer, and was not associated with any clinicopathological features. It is suggested that CLU and Ki67 have no distinct role in carcinogenesis. The further larger studies are needed to verify the results of this study. No significant financial relationships to disclose.

scholarly journals 1176P Expression and clinical significance of PD-L1 in small cell carcinoma of the esophagus

2020 ◽  
Vol 31 ◽  
pp. S779
Author(s):  
C. Zhang ◽  
G. Zhang ◽  
L. Xue ◽  
Q. Zeng ◽  
Z. Zhang ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Significance ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Carcinoma Of The Esophagus

The clinical significance of variant morphology small cell carcinoma of the lung

Lung Cancer ◽  
1989 ◽  
Vol 5 (1) ◽  
pp. 20
Author(s):  
S.C. Aisner ◽  
D. Ettinger ◽  
C. Mehta ◽  
J. Ruchdeschel ◽  
M. Abeloff ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Significance ◽  
Small Cell Carcinoma ◽  
Small Cell

scholarly journals Small Cell Carcinoma Esophagus: Experience of an Indian Tertiary Cancer Center

2021 ◽  
Author(s):  
Goutam Santosh Panda ◽  
Vanita Noronha ◽  
Subhash Yadav ◽  
Amit Joshi ◽  
Vijay Patil ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Median Overall Survival ◽  
Local Therapy ◽  
Cranial Irradiation ◽  
Small Cell ◽  
Cancer Center ◽  
Carcinoma Of The Esophagus ◽  
Stage Disease

Abstract Background: Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive tumor with no established standard treatment.Methods: This is a retrospective study of adult patients with histologically proven SCCE registered between February 2011 and March 2020 at Tata Memorial Hospital in Mumbai.Results: There were 56 patients with 29(51.8%) having limited-stage disease (LD) and 27(48.2%) having extensive-stage disease (ED). The median age was 58(IQR 51-65) years, 57.1% were men, 40% were smokers. Amongst LD-SCCE patients, 23 underwent local therapy i.e. radiation (19, 65.5%), surgery (4, 13.8%) and 27 received chemotherapy in neoadjuvant (23, 79.3%), concurrent (18, 62.1%) and adjuvant (4,13.8%) settings. Total 19 ED-SCCE patients (70.4%) received chemotherapy. Prophylactic cranial irradiation (PCI) was delivered to 11(37.9%) and 7(25.9%) patients with LD-SCCE and ED-SCCE, respectively. Significant grade ≥3 chemo-toxicities in patients with LD-SCCE and ED-SCCE included febrile neutropenia in 33.3% and 23.5%, anemia in 9.5% and 17.6%, and dyselectrolytemia in 14.3% and 11.8%, respectively. The median overall survival (OS) in LD-SCCE and ED-SCCE were 22.9 (95% CI 1.8-44.1) months and 11.8 (95% CI 7.3-16.4) months, respectively. Age <60years (p=0.004) and tumor epicenter in lower third esophagus (p=0.002) were good prognostic factors for OS in LD-SCCE and ED-SCCE patients respectively. The incidence of brain metastasis was low, both at presentation (1/27, 3.7%) and at relapse (5/56, 8.9%).Conclusion: Although the median overall survival of LD-SCCE is better than ED-SCCE, it is still under 2 years. Brain metastases are uncommon and PCI can be avoided with close clinico-radiological follow up.

scholarly journals Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Tim Mandelkow ◽  
Niclas C. Blessin ◽  
Eva Lueerss ◽  
Laura Pott ◽  
Ronald Simon ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Cell Density ◽  
Small Cell Carcinoma ◽  
Immune Cell ◽  
Cell Cancer ◽  
Small Cell ◽  
Urothelial Carcinomas ◽  
Significant Difference ◽  
Cell Bladder Cancer

Small-cell cancer of the urinary bladder is a rare but highly aggressive disease. It is currently unclear whether immune checkpoint therapies that have been approved for urothelial carcinomas will also be efficient in small-cell carcinomas. In this study, we analyzed potential predictors of response including PD-L1 expression and the quantity and location of tumor-infiltrating lymphocytes (TILs) in 12 small-cell and 69 “classical” urothelial cancers by immunohistochemistry. The analysis revealed that small-cell carcinomas were characterized by the virtual absence of PD-L1 expression and an “immune-excluded” phenotype with only a few TILs in the center of the tumor (CT). In small-cell carcinomas, the average immune cell density in the CT (CD3: 159±206, CD8: 87±169 cells/mm2) was more than 3 times lower than that in the urothelial carcinomas (CD3: 625±800, p<0.001; CD8: 362±626 cells/mm2, p=0.004) while there was no significant difference in the immune cell density at the invasive margin (IM) (small-cell carcinomas CD3: 899±733, CD8: 404±433 cells/mm2; urothelial carcinomas CD3: 1167±1206, p=0.31; CD8: 582±864 cells/mm2, p=0.27). Positive PD-L1 staining was found in 39% of urothelial cancers, but in only 8% of small-cell bladder cancer cases (p=0.04). Concordant with these data, a sharp decrease of PD-L1 positivity from >80% to 0% positive cells and of TILS in the CT from 466-1063 CD3-positive cells/mm2 to 50-109 CD3-positive cells/mm2 was observed in two cancers with clear-cut progression from “classical” urothelial to small-cell carcinoma. In conclusion, these data demonstrate that small-cell bladder cancer commonly exhibits an immune-excluded phenotype.

scholarly journals Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Baoqing Chen ◽  
Han Yang ◽  
Huali Ma ◽  
Qiaoqiao Li ◽  
Bo Qiu ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Therapeutic Modality ◽  
Cancer Center ◽  
Lesion Length ◽  
Carcinoma Of The Esophagus ◽  
Kaplan Meier ◽  
Ecog Ps

Abstract Background Small cell carcinoma of the esophagus (SCCE) is characterized by its progressive feature and poor prognosis. There is no consensus on a standard therapeutic modality for SCCE. In this study, we aimed to characterize the outcomes of primary SCCE patients treated by radiation therapy as part of treatment and investigate prognostic factors. Methods We retrospectively analyzed the data of 42 SCCE patients who were treated by RT as part of treatment at the Sun Yat-sen University Cancer Center from 2001 to 2014. The Kaplan-Meier and log-rank method were used to analyze survival. Cox’s hazard regression model was applied to determine prognostic factors. Results Of the 42 enrolled patients, 25 had limited disease (LD) and 17 with extensive disease (ED). The overall response rate (CR + PR) was 60.0% (21/35). The median overall survival time (OS) for whole and LD group were 12.9 and 36.8 months. The 1-, 3- and 5-year OS rates of the whole cohort were 64.9, 31.3, and 13.9%, respectively. OS was significantly longer in patients with ECOG performance score (ECOG PS) < 2 (p = 0.001), lesion length ≤ 5 cm (p = 0.001), and LD (p = 0.049). In the patients with LD, multivariate analysis indicated that combined with chemotherapy (P = 0.046) and higher radiation dose (P = 0.027) predicted better prognosis in OS. The overall rate of grade 3–4 toxicities in the whole cohort was 37.5%. In total, 65% (17/26) patients with recurrent disease died with the metastasis with or without the primary recurrence. Conclusion RT was one of the effective and safe treatments for locoregional control of SCCE. Lower ECOG PS score, shorter lesion length, treated with chemotherapy, and a higher dose of RT were identified as favorable independent prognostic factors.

The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4566-4566 ◽  
Author(s):  
S. P. Lynch ◽  
T. T. Vu ◽  
A. M. Kamat ◽  
H. B. Grossman ◽  
R. E. Millikan ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Cancer Center ◽  
Carcinoma Of The Bladder ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document